Citations

Clear

2303 citation(s) found for "Yu, Edward".

Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk
Tian, Yu , Kim, Andre E. , Harrison, Tabitha A. , Carreras‐Torres, Robert , Díez‐Obrero, Virginia , Drew, David A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Obón‐Santacana, Mireia , Ose, Jennifer , Duijnhoven, Fränzel J.B. van , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Brenner, Hermann , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Harlid, Sophia , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Prentice, Ross L. , Rennert, Gad , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Visvanathan, Kala , White, Emily , Woods, Michael O. , Wu, Anna H. , Casey, Graham , Kundaje, Anshul , Pardamean, Bens , Thomas, Duncan C. , Tsilidis, Konstantinos K. , Peters, Ulrike , Gauderman, W. James, Chang‐Claude, Jenny , Carreras-Torres, Robert , Drew, David A , Huyghe, Jeroen R , Jordahl, Kristina M , Murphy, Neil , Ulrich, Cornelia M , Ose, Jennifer , Peoples, Anita R , Ruiz-Narvaez, Edward , van Duijnhoven, Fränzel J B , Arndt, Volker , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Figueiredo, Jane C , Gruber, Stephen B , Harlid, Sophia , Hoffmeister, Michael , Jenkins, Mark A , Larsson, Susanna C , Marchand, Loïc Le , Li, Li , Giles, Graham G , Milne, Roger L , Nassir, Rami , Ogino, Shuji , Budiarto, Arif , Platz, Elizabeth A. , Potter, John D , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Wu, Anna H. , Kundaje, Anshul , Moreno, Victor , Pardamean, Bens , Thomas, Duncan C , Tsilidis, Konstantinos K , Chang-Claude, Jenny , Rennert, Gad , Harrison, Tabitha A , Tian, Yu , Nan, Hongmei , Obón-Santacana, Mireia , Diez-Obrero, Virginia , Bien, Stephanie A. , Lin, Yi , Qu, Conghui , Dimou, Niki , Hidaka, Akihisa , Morrison, John L. , Murphy, Neil , Ulrich, Cornelia M. , Shcherbina, Anna , Stern, Mariana Carla , Su, Yu-Ru , Arndt, Volker , Buchanan, Daniel D. , Chan, Andrew T. , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Giles, Graham G. , Milne, Roger L. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Wolk, Alicja , Campbell, Peter T. , Conti, David V. , Gunter, Marc J. , Lewinger, Juan Pablo , Moreno, Vı́ctor , Newcomb, Polly A. , Hsu, Li

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2022 | Volume: 114 | Issue: 8 | Pages: 1135-1148

10.1093/jnci/djac094 | PMID 35512400 Get It

Abstract Background The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. Methods We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2– or 3–degree-of-freedom joint test. A set-based score test was applied for rare genetic variants. Results The use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2–degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P < 1.2 × 10−4). Conclusion Genetic variants that modify the association between MHT and CRC risk were identified, offering new insights into pathways of CRC carcinogenesis and potential mechanisms involved.
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Li, Maggie , Beck, Evan J. , Laeyendecker, Oliver , Eby, Yolanda , Wouters, Camille, Chiklis, Gregory R., Block, William , McKie, Robert O., Joyner, Michael J. , Wiltshire, Timothy D. , Dietz, Allan B. , Gniadek, Thomas J. , Shapiro, Arell, Yarava, Anusha , Lane, Karen , Bloch, Evan M. , Cachay, Edward R. , Huamán, Moisés A. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Gerber, Jonathan M. , Sullivan, David , Wiltshire, Timothy D , Dietz, Allan B , Hanley, Daniel F , Bloch, Evan M , Shoham, Shmuel , Cachay, Edward R , Huaman, Moises A , Levine, Adam C , Paxton, James H , Gerber, Jonathan M , Gebo, Kelly A , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Laeyendecker, Oliver , Tobian, Aaron A.R. , Caturegli, Patrizio , Block, William, Hanley, Daniel F. , Shoham, Shmuel , Meisenberg, Barry R. , Anjan, Shweta , Casadevall, Arturo , Pekosz, Andrew

Mayo Clinic

Blood Advances | April 20, 2022 | Volume: 6 | Issue: 12 | Pages: 3678-3683

10.1182/bloodadvances.2022007410 | PMID 35443020 Get It

Abstract The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to δ or ο, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-δ COVID-19/postvaccination units and the hyperimmunoglobulin effectively neutralized all 3 variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region
Jordahl, Kristina M. , Shcherbina, Anna , Kim, Andre E. , Arndt, Volker , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Carreras‐Torres, Robert , Casey, Graham , Conti, David V. , Díez‐Obrero, Virginia , Dimou, Niki , Drew, David A. , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Obón‐Santacana, Mireia , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Pardamean, Bens , Prentice, Ross L. , Rennert, Gad , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Tian, Yu , Tsilidis, Konstantinos K. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Chang‐Claude, Jenny , Gauderman, W. James , Kundaje, Anshul , Peters, Ulrike , Arndt, Volker , Bien, Stephanie A , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Carreras-Torres, Robert , Chan, Andrew T , Dampier, Christopher H , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Harrison, Tabitha A , Hidaka, Akihisa , Hoffmeister, Michael , Huyghe, Jeroen R , Larsson, Susanna C , Mahesworo, Bharuno , Moreno, Victor , Morrison, John L , Nassir, Rami , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Peoples, Anita R , Pharoah, Paul D P , Platz, Elizabeth A. , Potter, John D , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Slattery, Martha L , Stern, Mariana Carla , Thomas, Duncan C , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Woods, Michael O , Chang-Claude, Jenny , Gauderman, W James , Hsu, Li , Kundaje, Anshul , Peters, Ulrike , Pardamean, Bens , Bouras, Emmanouil , Conti, David V , Nan, Hongmei , Obón-Santacana, Mireia , Papadimitriou, Nikos , Shcherbina, Anna , Vodicka, Pavel , Diez-Obrero, Virginia , Su, Yu-Ru , Lin, Yi , Wang, Jun , Qu, Conghui , Albanes, Demetrius , Bien, Stephanie A. , Buchanan, Daniel D. , Budiarto, Arif , Campbell, Peter T. , Cenggoro, Tjeng Wawan , Chan, Andrew T. , Dampier, Christopher H. , Devall, Matthew A M , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Morrison, John L. , Murphy, Neil , Newcomb, Polly A. , Palmer, Julie R. , Pharoah, Paul D.P. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Wolk, Alicja

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 19, 2022 | Volume: 31 | Issue: 5 | Pages: 1077-1089

10.1158/1055-9965.epi-21-1003 | PMID 35438744 Get It

Abstract Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r2 > 0.9 in the 10q24.2/COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.
Use of Self-Collected Saliva Samples for the Detection of SARS-CoV-2
Sogbesan, Kehinde, Sogbesan, Taiwo, Hata, D. Jane , White, Edward L, Daniel, Wyeth, Gasson, Samuel L, Jones, Dylan S, Vicari, Brittany R, Siclen, Carleen P Van, Palmucci, Carla, Marquez, Christopher P. , Parkulo, Mark A. , Thielen, Kent R. , Van Siclen, Carleen P, Nassar, Aziza

Mayo Clinic

Laboratory Medicine | April 15, 2022 | Volume: 53 | Issue: 6 | Pages: 580-584

10.1093/labmed/lmac051 | PMID 35672905 Get It

Abstract Objective Using a US Food and Drug Administration (FDA) emergency use authorization (EUA) reverse transcription polymerase chain reaction (RT-PCR) method, we examined the analytic performance accuracy of saliva specimens as compared to nasopharyngeal (NP) specimens in symptomatic patients. Correlation between test results and symptoms was also evaluated. Methods Over a 5-week period in 2020, 89 matched saliva and nasopharyngeal swabs were collected from individuals exhibiting symptoms consistent with SARS-CoV-2. Specimens were tested with an FDA EUA-approved RT-PCR method, and performance characteristics were compared. Results The concordance rate between saliva and nasopharyngeal testing was 93.26%. The mean cycle threshold value of saliva when compared to the NP specimen was 3.56 cycles higher. As compared to NP swab, saliva testing demonstrates acceptable agreement but lower sensitivity. Conclusion When compared to a reference method using NP swabs, the use of saliva testing proved to be a reliable method. Self-collected saliva testing for SARS-CoV-2 allows for a viable option when trained staff or collection materials are in short supply.
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
Day, Charles , Lu, Victor M. , Peterson, Timothy E., Power, Erica A. , Anderson, Jacob B. , Hamdan, Feda H. , Decker, Paul A. , Simons, Renae, Welby, John P. , Siada, Ruby , Ge, Jizhi, Kaptzan, Tatiana, Johnsen, Steven A. , Hinchcliffe, Edward H. , Nesvick, Cody L. , Choi, Jonghoon, Peterson, Timothy, Johnsen, Steven A , Day, Charles A , Power, Erica A , Anderson, Jacob B , Zhang, Liang , Choi, Jonghoon , Decker, Paul A. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | April 9, 2022 | Volume: 24 | Issue: 10 | Pages: 1700-1711

10.1093/neuonc/noac093 | PMID 35397475 Get It

Abstract Background H3K27M-mutant diffuse midline glioma (DMG) is a lethal brain tumor that usually occurs in children. Despite advances in our understanding of its underlying biology, efficacious therapies are severely lacking. Methods We screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant DMG cell lines with cell viability as the outcome. Results were validated for clinical relevance and mechanistic importance using patient specimens from biopsy and autopsy, patient-derived cell lines, inhibition by gene knockdown and small molecule inhibitors, and patient-derived xenografts. Results Kinase inhibitors were highly toxic to H3K27M-mutant DMG cells. Within this class, STAT3 inhibitors demonstrated robust cytotoxic activity in vitro. Mechanistic analyses revealed one form of activated STAT3, phospho-tyrosine- 705 STAT3 (pSTAT3), was selectively upregulated in H3K27M-mutant cell lines and clinical specimens. STAT3 inhibition by CRISPR/Cas9 knockout, shRNA or small molecule inhibition reduced cell viability in vitro, and partially restored expression of the polycomb repressive mark H3K27me3, which is classically lost in H3K27M-mutant DMG. Putative STAT3-regulated genes were enriched in an H3K27M-knockout DMG cell line, indicating relative gain of STAT3 signaling in K27M-mutant cells. Treatment of patient-derived intracranial xenografts with WP1066, a STAT3 pathway inhibitor currently in clinical use for pediatric brain tumors, resulted in stasis of tumor growth, and increased overall survival. Finally, pSTAT3(Y705) was detected in circulating plasma extracellular vesicles of patients with H3K27M-mutant DMG. Conclusions STAT3 is a biologically relevant therapeutic target in H3K27M-mutant DMG. STAT3 inhibition should be considered in future clinical trials.
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Popat, Rakesh , Hulin, Cyrille , Richardson, PG, Facon, T., Larsen, Jeremy T. , Minnema, M., Abdallah, Al-Ola, Badros, Ashraf , Knop, Stefan , Stadtmauer, Edward A. , Chen, M, Nguyen, Tiffany, Amin, Alpesh, Peluso, Teresa, Donk, Niels W.C.J. van de , Popat, Rakesh , Jagannath, Sundar , Oriol, Albert , Weisel, Katja C , Abdallah, Al-Ola , Lonial, Sagar

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 14-15

10.1097/01.hs9.0000829600.37424.88 Get It

Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes—protocol for a population-based retrospective study
Farquhar, Hamish , Edwards, Adrienne L. , Matteson, Eric L. , Thiessen, Rennae, Ganly, Edward, Beckert, Lutz , Stamp, Lisa K.

Mayo Clinic

BMJ Open | April 5, 2022 | Volume: 12 | Issue: 4 | Pages: e050934

10.1136/bmjopen-2021-050934 | PMID 35383056 Get It

Introduction Rheumatoid arthritis (RA) affects approximately 0.5%–1% of the general population. Clinically significant interstitial lung diseases (ILD) develops in just under 10% of people with RA, and subclinical disease is more common. Little is known about RA-ILD in New Zealand (NZ), or the number of persons with RA in Canterbury, NZ. This study aims to determine: (1) incidence and prevalence of RA, (2) incidence and prevalence of RA-ILD, (3) clinical characteristics and risk factors for the development of RA-ILD, (4) long-term outcomes of RA-ILD, in the population resident within the Canterbury District Health Board (CDHB) catchment area. Methods and analysis Persons aged 18 years of age and older, and resident in the region covered by the CDHB with RA as well as RA-ILD will be identified by retrospective review of medical records. Prevalent as well as incident cases of RA between 1 January 2006 and 31 December 2008 and between 1 January 2011 and 31 December 2013 will be identified, and followed until 30 June 2019. Existing as well as incident cases of RA-ILD during this time will be identified. The association between the development of ILD and clinical characteristics and environmental exposures will be examined using Cox-proportional hazard models. Kaplan-Meier methods will be used to estimate survival rates for patients with RA-ILD. Mortality for people with RA and RA-ILD will also be compared with the general population of the CDHB. Ethics and dissemination Data will be obtained by retrospective review of medical records. Deidentified patient data will be stored in a secure online database. Data on individual patients will not be released, and all results will only be published in aggregate. Ethical approval has been obtained from the University of Otago Human Research Ethics Committee (REF HD18/079). Results will be published in peer-reviewed medical journals and presented at conferences. Trial registration number ACTRN12619001310156; Pre-results.
Lack of clinically relevant differences in safety and pharmacokinetics after second‐dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis
Cascino, Gregory D. , Wheless, James W. , Sperling, Michael R. , Desai, Jay , Vázquez, Blanca , Samara, Emil, Misra, Sunita N. , Carrazana, Enrique , Group, for the DIAZ.001.05 Study, Wheless, James W , Hogan, R Edward , Sperling, Michael R , Misra, Sunita N , Carrazana, Enrique , Rabinowicz, Adrian L , Cascino, Gregory D , Tarquinio, Daniel Charles , Rabinowicz, Adrián L. , Group, for the DIAZ.001.05 Study

Mayo Clinic

Epilepsia | April 4, 2022 | Volume: 63 | Issue: 7 | Pages: 1714-1723

10.1111/epi.17249 | PMID 35377464 Get It

AbstractObjectiveCurrent diazepam nasal spray labeling requires waiting 4 h before administering a second dose. The objective of the current analyses was to examine safety and pharmacokinetic profiles of second doses of diazepam nasal spray given 0−4 h after the first dose.MethodsTwo datasets were analyzed. The first, a long‐term, repeat‐dose safety study of diazepam nasal spray, compared rates of treatment‐emergent adverse events (TEAEs), serious TEAEs, and treatment‐related TEAEs for patients receiving ≥1 second dose ≤4 h versus all second doses >4 h after the first. The second was a population pharmacokinetic analysis using data from three phase 1 studies to model drug exposure when a second dose of diazepam nasal spray was administered across multiple time points (1 min−4 h) following the first dose.ResultsIn the repeat‐dose safety study, a second dose of diazepam nasal spray was administered ≤24 h after the first to treat 485 seizure clusters in 79 patients. Rates of TEAEs were similar between patients receiving ≥1 second dose in ≤4 h (89.5%, n = 38) compared with >4–24 h only (80.5%, n = 41). The most common treatment‐related TEAEs were associated with nasal discomfort, which was mild or moderate and transient. There were no reports of respiratory or cardiac depression. The pharmacokinetic simulations of second doses predicted comparable elevations of plasma diazepam concentrations with administrations across a range of intervals after the first dose (1 min−4 h).SignificanceThese data indicate that the safety and pharmacokinetic profiles of a second dose of diazepam nasal spray administered within 4 h of the first dose are consistent with those associated with current labeling. This is potentially important for patients with seizure clusters who have a recurrent seizure within 4 h of first treatment and might benefit from immediate retreatment to reduce the risk of progression to status epilepticus.
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
Bloch, Evan M. , Tobian, Aaron A.R. , Gniadek, Thomas J. , Cachay, Edward R. , Kafka, Kimberly, Marshall, Christi E., Heath, Sonya L. , Forthal, Donald N. , Fukuta, Yuriko , Huamán, Moisés A. , Ziman, Alyssa , Adamski, Jill , Gerber, Jonathan M. , Cruser, Daniel, Patel, Bela , Metcalf, Ryan A. , Reisler, Ronald B. , Yarava, Anusha , Lane, Karen , McBee, Nichol , Gawad, Amy L., Abinante, Matthew, Broderick, Patrick , Sullivan, David , Ziman, Alyssa , Adamksi, Jill , Raval, Jay S , Metcalf, Ryan A , Tobian, Aaron A R , Huaman, Moises A , Sullivan, David J , Shoham, Shmuel , Hanley, Daniel F. , Meisenberg, Barry R. , Shenoy, Aarthi , Paxton, James H , Levine, Adam C , Kassaye, Seble , Mosnaim, Giselle S , Anjan, Shweta , Raval, Jay S. , Zand, Martin S. , Broderick, Patrick B., Casadevall, Arturo , Gebo, Kelly A

Mayo Clinic

Transfusion | March 30, 2022 | Volume: 62 | Issue: 5 | Pages: 933-941

10.1111/trf.16871 | PMID 35352362 Get It

AbstractConvalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID‐19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID‐19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID‐19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Kulke, Matthew H. , Ou, Fang-Shu, Niedzwiecki, Donna, Huebner, Lucas, Kunz, Pamela L. , Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Meyerhardt, Jeffrey A, Venook, Alan, Niedzwiecki, Donna , Meyerhardt, Jeffrey A. , Kunz, Pamela , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Kulke, Matthew H , Ou, Fang-Shu, Huebner, Lucas, Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Venook, Alan

Mayo Clinic

Endocrine-Related Cancer | March 25, 2022 | Volume: 29 | Issue: 6 | Pages: 335-344

10.1530/erc-21-0239 | PMID 35324465 Get It

Treatment with the MTOR inhibitor everolimus improves progression-free survival (PFS) in pancreatic neuroendocrine tumors (pNETs), but it is not known if the addition of a VEGF pathway inhibitor to an MTOR inhibitor enhances antitumor activity. We performed a randomized phase II study evaluating everolimus with or without bevacizumab in patients with advanced pNETs. One hundred and fifty patients were randomized to receive everolimus 10 mg daily with or without bevacizumab 10 mg/kg i.v. every 2 weeks. Patients also received standard dose of octreotide in both arms. The primary endpoint was PFS, based on local investigator review. Treatment with the combination of everolimus and bevacizumab resulted in improved progression-free survival compared to everolimus (16.7 months compared to 14.0 months; one-sided stratified log-rank P = 0.1028; hazard ratio (HR) 0.80 (95% CI 0.56–1.13)), meeting the predefined primary endpoint. Confirmed tumor responses were observed in 31% (95% CI 20%, 41%) of patients receiving combination therapy, as compared to only 12% (95% CI 5%, 19%) of patients receiving treatment with everolimus ( P = 0.0053). Median overall survival duration was similar in the everolimus and combination arm (42.5 and 42.1 months, respectively). Treatment-related toxicities were more common in the combination arm. In summary, treatment with everolimus and bevacizumab led to superior PFS and higher response rates compared to everolimus in patients with advanced pNETs. Although the higher rate of treatment-related adverse events may limit the use of this combination, our results support the continued evaluation of VEGF pathway inhibitors in pNETs.